Nutriband (NASDAQ:NTRB – Get Free Report) and ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.
Volatility & Risk
Nutriband has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Nutriband and ARS Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
Earnings and Valuation
This table compares Nutriband and ARS Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nutriband | $2.04 million | 43.39 | -$8.23 million | ($0.53) | -13.74 |
| ARS Pharmaceuticals | $84.28 million | 4.80 | -$171.30 million | ($2.18) | -1.87 |
Nutriband has higher earnings, but lower revenue than ARS Pharmaceuticals. Nutriband is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Nutriband and ARS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nutriband | -430.35% | -109.07% | -95.54% |
| ARS Pharmaceuticals | -184.24% | -256.67% | -69.63% |
Insider and Institutional Ownership
19.7% of Nutriband shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 52.2% of Nutriband shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
ARS Pharmaceuticals beats Nutriband on 8 of the 14 factors compared between the two stocks.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
